Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers (NiteCAPP)

February 15, 2024 updated by: Christina McCrae, University of South Florida

Over the next 30 years, more than 10 million persons living with dementia in the United States will receive care at home from an unpaid and untrained family caregiver. At home care is preferred by caregivers and persons with dementia alike, but increases the caregiver's risk of insomnia and related negative health outcomes, including depression, anxiety, cognitive disturbances and poor quality of life. Cognitive behavioral therapy for insomnia (CBT-I) is a highly effective and established evidence based treatment for adults of all ages. Although relatively understudied in dementia caregivers, the research by our group and others suggests CBT-I is also efficacious in caregivers. Our team developed a brief (4 session) CBT-I protocol specifically adapted for dementia caregivers (CBT-I) and has shown in person and remote (i.e. telehealth) delivery of this protocol significantly reduces insomnia symptoms and improves mood (moderate to large effects). Given demands on caregivers' time and limited availability of trained CBT-I providers, a web-based version of CBT-I (WebCBT-I; the online treatment will be called NiteCAPP) is needed to increase the accessibility of this efficacious treatment. WebCBT-I will allow for flexible at home scheduling, and the skills needed to monitor caregiver treatment progress can be quickly and efficiently taught to healthcare providers. The overarching goal of this project is to develop and test WebCBT-I in caregivers of persons with dementia.

Objectives

  1. To examine the clinical and health characteristics, including sleep, pain, fatigue, cognitive abilities, and cardiovascular health in dementia caregivers with insomnia.
  2. To examine changes in the primary clinical outcomes, including complaints of poor sleep, and fatigue.
  3. To examine changes in the secondary clinical outcomes, including mood, daytime functioning, cognitive functioning, and cardiovascular health.
  4. To examine the mechanistic variables, including arousal (heart rate variability, HRV).

Study Overview

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Missouri
      • Columbia, Missouri, United States, 65212
        • Recruiting
        • University of Missouri
        • Contact:
          • Riley Stephens
        • Contact:
          • Christina McCrae

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

CAREGIVER

Inclusion Criteria:

  • 18+ yrs
  • Dementia caregiver living with person with dementia
  • willing to be randomized, 4. read/understand English
  • insomnia diagnosis
  • no prescribed or over-the-counter sleep meds or stabilized 6+ weeks.

Insomnia:

  • complaints for 6+ mos
  • adequate opportunity and circumstances for sleep
  • 1+ of the following: difficulty falling asleep, staying asleep, or waking too early
  • daytime dysfunction (mood, cognitive, social, occupational) due to insomnia
  • Screening interview indicates Insomnia Severity Index score ≥11 or Insomnia Severity Index score 9-10
  • baseline diaries indicate >30 mins of sleep onset latency or wake after sleep onset on 3+ nts.

Exclusion Criteria:

  • unable to consent
  • cognitive impairment [Telephone Interview for Cognitive Status (TICS) <25 or Mini Mental State Examination (MMSE) <26]
  • sleep disorder other than insomnia [i.e., sleep apnea (apnea/hypopnea index, AHI >15)]
  • bipolar or seizure disorder
  • other major psychopathology except depression or anxiety (e.g., suicidal ideation/intent, psychosis)
  • severe untreated psychiatric comorbidity
  • psychotropic or other medications (e.g., beta-blockers) that alter sleep
  • non-pharmacological tx for sleep or mood outside current trial.

PERSONS WITH DEMENTIA

Inclusion Criteria:

  • 18+ yrs
  • Persons with dementia living with caregiver
  • Have an eligible caregiver
  • willing to be randomized

Exclusion Criteria:

• Person with dementia or legally authorized representative is unable to consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NiteCAPP: Online Cognitive Behavioral Therapy for Insomnia
This is a pilot trial with one treatment condition (CBT-I).
Participants will complete 4 web-based CBT- I sessions. Lesson 1: Sleep Hygiene and Stimulus Control Lesson 2: Sleep Restriction and Relaxation Strategies Lesson 3: Identifying and Restructuring Dysfunction Thoughts Lesson 4: Practical Recommendations, Review, and Maintenance of Change

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insomnia Severity Index
Time Frame: 6 weeks
Insomnia severity measurement; min: 0 max:28; higher score means greater insomnia severity
6 weeks
Daily Electronic Sleep and Pain Diaries - Sleep Onset Latency
Time Frame: 6 weeks
Subjective sleep onset latency (time to fall asleep)
6 weeks
Daily Electronic Sleep and Pain Diaries - Wake-time After Sleep Onset
Time Frame: 6 weeks
Subjective time awake after sleep onset
6 weeks
Daily Electronic Sleep and Pain Diaries - Total Sleep Time
Time Frame: 6 weeks
Subjective total sleep time
6 weeks
Daily Electronic Sleep and Pain Diaries - Sleep Efficiency
Time Frame: 6 weeks
Subjective sleep efficiency
6 weeks
Daily Electronic Sleep and Pain Diaries - Pain Intensity & Unpleasantness
Time Frame: 6 weeks
Pain Intensity & Unpleasantness
6 weeks
Daily Electronic Sleep and Pain Diaries - Medication Consumption
Time Frame: 6 weeks
Sleep and pain medication consumption
6 weeks
Objective Daily Sleep Actiwatch-2 - Sleep Onset Latency
Time Frame: 6 weeks
Objective sleep onset latency (time to fall asleep)
6 weeks
Objective Daily Sleep Actiwatch-2 - Wake-time After Sleep Onset
Time Frame: 6 weeks
Objective time awake after sleep onset
6 weeks
Objective Daily Sleep Actiwatch-2 - Total Sleep Time
Time Frame: 6 weeks
Objective total sleep time
6 weeks
Objective Daily Sleep Actiwatch-2 - Sleep Efficiency
Time Frame: 6 weeks
Objective sleep efficiency
6 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
State Trait Anxiety Inventory (STAI-Y1)
Time Frame: 6 weeks
Assessment of anxiety symptoms - min: 0 max:60; higher score means higher anxiety
6 weeks
Beck Depression Inventory Second Edition (BDI- II)
Time Frame: 6 weeks
Depressive symptom assessment - min: 0 max: 63; Higher score means higher severity of depression
6 weeks
Perceived Stress Scale (PSS)
Time Frame: 6 weeks
Perception of stress - min: 0; max:40 - higher scores indicate higher perceived stress
6 weeks
Kingston Caregiver Stress Scale
Time Frame: 6 weeks
Caregiver stress measurement - min:10 max:50 - higher score indicates higher caregiver stress
6 weeks
Dysfunctional Attitudes/Beliefs about Sleep (DBAS)
Time Frame: 6 weeks
evaluates sleep-related beliefs, expectations and attitudes regarding the causes, consequences, and potential treatments of sleep issues - higher scores indicates more dysfunctional beliefs and attitudes
6 weeks
Caregiver Functional Unit Scale
Time Frame: 6 weeks
Assessment of the stability of the patient-caregiver dyad - higher score indicates lower stability
6 weeks
Online Cognitive Assessment - Stroop
Time Frame: 6 weeks
Determine level of cognitive functioning
6 weeks
Online Cognitive Assessment - Sternberg
Time Frame: 6 weeks
Determine level of cognitive functioning
6 weeks
Online Cognitive Assessment - Wisconsin Card Sorting Task
Time Frame: 6 weeks
Determine level of cognitive functioning
6 weeks
Cognitive Failures Questionnaire
Time Frame: 6 weeks
Self-reported failures in perception, memory, and motor function - min:0 max: 100 - higher score indicates greater cognitive failure
6 weeks
Dementia Patient's Caregiver Quality of Life Scale
Time Frame: 6 weeks
Assessment of caregiver quality of life - min: 0 max:100 - higher score indicates good quality of life
6 weeks
Zarit Burden Scale
Time Frame: 6 weeks
Caregiver burden measurement - min: 0 max: 48 - higher score indicated higher caregiver burden
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christina McCrae, University of Missouri-Columbia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 2, 2022

Primary Completion (Estimated)

March 31, 2026

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

November 10, 2020

First Submitted That Met QC Criteria

November 16, 2020

First Posted (Actual)

November 17, 2020

Study Record Updates

Last Update Posted (Actual)

February 20, 2024

Last Update Submitted That Met QC Criteria

February 15, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dementia

Clinical Trials on Web-based Cognitive Behavior Therapy for Insomnia (CBT-I)

3
Subscribe